Linaclotide in irritable bowel syndrome with constipation: A phase 3 randomized trial in China and other regions
Journal of Gastroenterology and Hepatology Jan 14, 2018
Yang Y, et al. - Linaclotide's efficacy and safety were evaluated among patients with irritable bowel syndrome with constipation (IBS-C) in China and other regions. In a predominantly Chinese IBS-C population, once-daily 290-μg linaclotide improved bowel habits, abdominal symptoms, and global measures.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
